Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LIGAND PHARMACEUTICALS INCORPORATED

(LGND)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ligand Pharmaceuticals Incorporated : Pharma to Receive $7 Million in Milestone Payments After Partner Jazz Pharma Launches Rylaze for Leukemia and Lymphoma

07/21/2021 | 11:43am EDT


© MT Newswires 2021
All news about LIGAND PHARMACEUTICALS INCORPORATED
09/16LIGAND PHARMACEUTICALS INCORPORATED : September Corporate Presentation
PU
09/15LIGAND PHARMACEUTICALS INCORPORATED : H.C. Wainwright Investor Conference
PU
09/14LIGAND PHARMACEUTICALS INCORPORATED : September Corporate Presentation
PU
09/09LIGAND PHARMACEUTICALS INCORPORATED : September Investor Roadshow
PU
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) added to S&P 600
CI
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) added to S&P 600 Health Care
CI
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) dropped from S&P 400
CI
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) dropped from S&P 400 Health Care
CI
09/07LIGAND PHARMACEUTICALS INCORPORATED( : LGND) dropped from S&P 400 - Biotechnolog..
CI
08/31UPDATE : Ligand Pharmaceuticals Partner Secures China Approval for Classical Hod..
MT
More news
Analyst Recommendations on LIGAND PHARMACEUTICALS INCORPORATED
More recommendations
Financials (USD)
Sales 2021 270 M - -
Net income 2021 67,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 35,8x
Yield 2021 -
Capitalization 2 414 M 2 414 M -
Capi. / Sales 2021 8,95x
Capi. / Sales 2022 13,0x
Nbr of Employees 155
Free-Float 95,2%
Chart LIGAND PHARMACEUTICALS INCORPORATED
Duration : Period :
Ligand Pharmaceuticals Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LIGAND PHARMACEUTICALS INCORPORATED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 144,73 $
Average target price 207,00 $
Spread / Average Target 43,0%
EPS Revisions
Managers and Directors
John L. Higgins Chief Executive Officer & Director
Matthew William Foehr President & Chief Operating Officer
Matthew Edward Korenberg Chief Financial Officer & Executive VP-Finance
John W. Kozarich Chairman
Eric Vajda Vice President-Preclinical Research & Development
Sector and Competitors
1st jan.Capi. (M$)
LIGAND PHARMACEUTICALS INCORPORATED45.53%2 414
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420